Muscarinic Antagonists/adverse effects

Requena, G. ., Czira, A. ., Banks, V. ., Wood, R. ., Tritton, T. ., Castillo, C. ., … Ismaila, A. S. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 2039–2054. http://doi.org/10.2147/copd.s408688
Halpin, D. M. G., Rothnie, K. J., Banks, V. ., Czira, A. ., Compton, C. ., Wood, R. ., … Vogelmeier, C. F. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417–2429. http://doi.org/10.2147/copd.s370540
Rebordosa, C. ., Plana, E. ., Rubino, A. ., Aguado, J. ., Martinez, D. ., Lei, A. ., … Rivero-Ferrer, E. . (2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715–1733. http://doi.org/10.2147/copd.s363997
Sansbury, L. B., Rothnie, K. J., Bains, C. ., Compton, C. ., Anley, G. ., & Ismaila, A. S. (2021). Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Int J Chron Obstruct Pulmon Dis, 16, 2591–2604. http://doi.org/10.2147/copd.s318969